Back to drug

The Drug-Induced Respiratory Disease Website

Osimertinib

XXIV.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Taking the patient off osimertinib is indicated (PMID 31882494) plus corticosteroid therapy

Publications

Le Guen Y, Lederlin M, Triquet L, Lesouhaitier M, Le Tulzo Y, Ricordel C

[Pulmonary manifestations induced by osimertinib].

Revue des maladies respiratoires 2021 Dec 27;; — 2021 Dec 27

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs 2021 04;39;571-577 — 2021 04 — 571-577

Lu H, Dowell J

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

In vivo (Athens, Greece) 2020 Jan-Feb;34;315-319 — 2020 Jan-Feb — 315-319

Fan M, Mo T, Shen L, Yang L

Osimertinib-induced severe interstitial lung disease: A case report.

Thoracic cancer 2019 Jul;10;1657-1660 — 2019 Jul — 1657-1660

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Apr 20;35;1288-1296 — 2017 Apr 20 — 1288-1296

Diagnosing DIRD